vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and UPEXI, INC. (UPXI). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $8.1M, roughly 1.7× UPEXI, INC.). Gossamer Bio, Inc. runs the higher net margin — -342.3% vs -2222.1%, a 1879.8% gap on every dollar of revenue. On growth, UPEXI, INC. posted the faster year-over-year revenue change (101.0% vs 47.1%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
GOSS vs UPXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $8.1M |
| Net Profit | $-47.2M | $-178.9M |
| Gross Margin | — | 83.3% |
| Operating Margin | -333.6% | -2177.9% |
| Net Margin | -342.3% | -2222.1% |
| Revenue YoY | 47.1% | 101.0% |
| Net Profit YoY | -43.0% | -13649.6% |
| EPS (diluted) | $-0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $8.1M | ||
| Q3 25 | $13.3M | $9.2M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | $95.8M | $5.0M | ||
| Q1 24 | $0 | $5.2M |
| Q4 25 | $-47.2M | $-178.9M | ||
| Q3 25 | $-48.2M | $66.7M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-3.8M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | $49.2M | $-15.7M | ||
| Q1 24 | $-41.9M | $-4.1M |
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 89.6% | ||
| Q2 25 | — | 79.4% | ||
| Q1 25 | — | 49.3% | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | — | 67.3% | ||
| Q2 24 | — | 31.0% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -333.6% | -2177.9% | ||
| Q3 25 | -369.4% | — | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | — | -113.5% | ||
| Q4 24 | — | -26.8% | ||
| Q3 24 | — | -30.6% | ||
| Q2 24 | 54.3% | -265.2% | ||
| Q1 24 | — | -96.5% |
| Q4 25 | -342.3% | -2222.1% | ||
| Q3 25 | -362.7% | 722.4% | ||
| Q2 25 | — | -161.5% | ||
| Q1 25 | — | -121.2% | ||
| Q4 24 | — | -32.5% | ||
| Q3 24 | — | -37.3% | ||
| Q2 24 | 51.4% | -312.4% | ||
| Q1 24 | — | -78.9% |
| Q4 25 | $-0.21 | — | ||
| Q3 25 | $-0.21 | $0.76 | ||
| Q2 25 | — | $0.83 | ||
| Q1 25 | — | $-2.87 | ||
| Q4 24 | — | $-1.24 | ||
| Q3 24 | — | $1.55 | ||
| Q2 24 | $0.22 | $-15.66 | ||
| Q1 24 | $-0.19 | $-4.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $48.7M |
| Total Assets | $172.2M | $271.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | — | ||
| Q3 25 | $180.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $354.5M | — | ||
| Q1 24 | $244.4M | — |
| Q4 25 | $-122.8M | $48.7M | ||
| Q3 25 | $-82.3M | $210.8M | ||
| Q2 25 | — | $90.1M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $3.8M | ||
| Q3 24 | — | $5.0M | ||
| Q2 24 | $81.5M | $6.5M | ||
| Q1 24 | $26.7M | $22.1M |
| Q4 25 | $172.2M | $271.1M | ||
| Q3 25 | $208.8M | $419.7M | ||
| Q2 25 | — | $123.8M | ||
| Q1 25 | — | $15.1M | ||
| Q4 24 | — | $17.5M | ||
| Q3 24 | — | $18.6M | ||
| Q2 24 | $373.4M | $23.5M | ||
| Q1 24 | $259.4M | $56.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.7M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $-2.7M | ||
| Q3 25 | $-36.2M | $-9.8M | ||
| Q2 25 | — | $-8.4M | ||
| Q1 25 | — | $-778.7K | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | $116.3M | $-101.4K | ||
| Q1 24 | $-52.3M | $783.5K |
| Q4 25 | — | $-2.7M | ||
| Q3 25 | — | $-9.8M | ||
| Q2 25 | — | $-8.8M | ||
| Q1 25 | — | $-809.3K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $600.9K |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | -106.0% | ||
| Q2 25 | — | -205.4% | ||
| Q1 25 | — | -25.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -20.5% | ||
| Q1 24 | — | 11.5% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | — | 9.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | 0.0% | 18.5% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
